California Cancer Reporting System Standards, Volume III

IF1168: Primary Site, TNM Path Stage Valid B – Ed 7 (COC)

OWNER

CoC

EDIT SETS

California Hospital Transmit

Eureka Admission Level

Eureka Tumor Level

FIELDS

TNM Clin T [NAACCR #940]

TNM Clin N [NAACCR #950]

TNM Clin M [NAACCR #960]

TNM Path Stage Group [NAACCR #910]

Primary Site [NAACCR #400]

Histologic Type ICD-O-3 [NAACCR #522]

Behavior Code ICD-O-3 [NAACCR# 523]

Date of Diagnosis [NAACCR #390]

TNM Edition Number [NAACCR #1060]

TNM Path Descriptor [NAACCR #920]

Age at Diagnosis [NAACCR #230]

Grade [NAACCR #440]

CS Site-Specific Factor 1 [NAACCR #2880]

CS Site-Specific Factor 10 [NAACCR #2864]

CS Site-Specific Factor 13 [NAACCR #2867]

CS Site-Specific Factor 15 [NAACCR #2869]

CS Site-Specific Factor 16 [NAACCR #2870]

CS Site-Specific Factor 25 [NAACCR #2879]

Sex [NAACCR #220]

Type of Reporting Source [NAACCR# 500]

TABLE

AC7G2016.DBF

PAST7VAL.DBF

SVALTEST.DBF

MESSAGE

1. IF1168: Inconsistency between TNM categories T [value] N [value] M [value] and assigned TNM stage [value]

2. IF1168: Combination of T [value] N [value] M [value] is invalid for TNM staging

3. IF1168: T [value] N [value] M [value], staging parameter for [value], inconsistent with TNM stage [value]

4. IF1167: Combination T [value] N [value] M [value], staging parameter for [value], invalid for TNM staging

specification

This edit is skipped if any of the following conditions are true:

1. This edit is skipped if any of the following conditions are true:

2. Year of Date of Diagnosis is less than 2016, blank (unknown), or invalid

3. Type of Reporting Source = 7 (Death Certificate Only)

4. Histologic Type ICD-O-3 is blank

5. Behavior Code ICD-O-3 = 0 (benign) or 1 (borderline)

6. TNM Edition Number is not = 07, U7, 88

7. TNM Path Stage Group is blank

8. TNM Path T or TNM Path M is blank

9. TNM Path Descriptor = 4 or 6

The purpose of this edit is to validate the coded TNM categories, and site-specific staging parameters where used, with the coded Stage Group assignments. Some TNM chapters require elements in addition to T, N, and M categories, such as grade or mitotic rate. for correct stage assignment. In this edit description, these elements are called staging parameters. The edit will not be skipped but will pass if any of TNM Clin N or a required staging parameter is blank. (The exception for TNM Path N allows for the possible coding of TNM Path N as blank for site/histology group 39; if blank, TNM Path N will be converted to "88" for the edit.)

The edit compares the combination of TNM Path T, TNM Path N, TNM Path M categories, and staging parameter where required, with TNM Path Stage Group. The edit is skipped if TNM Path Descriptor is 4 or 6, indicating stage assignment after neoadjuvant treatment.  (With neoadjuvaant treatment, combinations of T, N, M and staging parameters are allowed that would not be valid otherwise.)

The designation of "c" or "p" within the individual T, N, and M codes is ignored for this edit.  Valid codes for individual fields (TNM Path T, TNM Path N, TNM Path M, TNM Path Stage Group), and for these individual fields by primary site, are checked in other edits.   

An edit failure is returned if the Path Stage Group is inconsistent with the expected group assignment for the coded T, N, M, and staging parameter if required, based on

the AJCC stage tables. If a T, N, or M value is coded that is not included in the AJCC stage tables -- for example T4 is coded but only T4A and T4B are staged -- the stage assignment will not be checked and the edit will pass.   

An edit failure is also returned if either the coded Path Stage Group returns "ERROR" from the lookup table, meaning that the combination of T, N, M, and staging parameter is invalid. Invalid combinations include T0N0M0/M0I+; T in situ with positive N and/or positive M category; and a Testis stage with an invalid S category. An invalid S category results  when one or more of the 3 site-specific factors required to determine the category (SSF 13-AFP, SSF 15-hCG, SSF 16-LDH) is coded 988, meaning not applicable.

The site/histology groups are listed below. The number next to each site title indicates the respective chapter in the AJCC Cancer Staging Manual, Edition 7.The site/histology groups and group stage values are identified by site and histology in the edit Primary Site, Stage Group 2016 - Ed 7. Subdivisions of some groups were required for this edit; they are identified below with their criteria. Site-specific staging parameters are also identified. The description does not include the list of TNM categories, staging parameters, and stage groups; this information is contained in a table within EditWriter that contains around 14,700 records.

Site/histology groups 49, Carcinoma of Conjunctiva, 50, Malignant Melanoma of Conjunctiva, 52, Retinoblastoma, 53, Carcinoma of Lacrimal Gland, 54, Sarcoma of Orbit, 55, Ocular Adnexal Lymphoma, are listed below.  However, staging for these site/histology groups is not validated by this edit, as no stage grouping applies. The T, N, M codes for site/histology groups 49, 50, 52, 53, 54, and 55 are validated in the edits Primary Site, T 2016 - Ed 7, Primary Site, N 2016 - Ed 7, and Primary Site, M 2016 - Ed 7.

Site/histology group 57A, Lymphoid Neoplasms, is also listed below.  However, staging for 57A does not include T, N, and M components, and stage is not validated in this edit.  The T, N, M codes for site/histology group 57A are validated in the edits Primary Site, T 2016 - Ed 7, Primary Site, N 2016 - Ed 7, and Primary Site, M 2016 - Ed 7. Stage group for 57A is validated in the edit Primary Site, Stage Group 2016 - Ed 7.  Site/histology group 55, Ocular Adnexal Lymphoma, will pass this edit if coded as Lymphoma (T=88,N=88,M=88,Stage Group = stage from Ch 57), or as Ocular Adnexal Lymphoma (T=T from Ch 55, N=N from Ch 55, M=M from Ch 55, Stage Group = 88).  

29. Cutaneous Squamous Cell Carcinoma and other Cutaneous Carcinomas

30. Merkel Cell Carcinoma

31. Melanoma of the Skin

32. Breast

33. Vulva

34. Vagina

35. Cervix Uteri

36. Corpus Uteri

1. Corpus Uteri: Carcinomas

2. Corpus Uteri: Leiomyosarcoma and Endometrial Stromal Sarcoma

3. Corpus Uteri: Adenosarcoma

37. Ovary and Peritoneal Carcinomas

1. Ovary

2. Peritoneal Carcinomas

38. Fallopian Tube

39. Gestational Trophoblastic Tumors

Staging Parameter: Prognostic Scoring Index as collected in CS SSF 1

40. Penis

41. Prostate

Division for Staging:

1. PSA: 988, 997, 998, 999

2. PSA: 001-099

3. PSA: 100-199

4. PSA: 200-980

Staging Parameter: Gleason Score: As collected in CS SSF 8 or CS SSF 10, whichever value is greater, excluding 988, 998, and 999 for CS SSF 8

42. Testis

Staging Parameter: S value, based on calculation of: post-orchiectomy AFP value as collected in CS SSF 13, post-orchiectomy hCG value as collected in CS SSF 15, post-orchiectomy LDH range as collected in CS SSF 16

43. Kidney

44. Renal Pelvis and Ureter

45. Urinary Bladder

46. Urethra

47. Adrenal

1. Adrenal Cortex

2. Adrenal Cortical Carcinoma

48. Carcinoma of the Eyelid

49. Conjunctiva

50. Malignant Melanoma of the Conjunctiva

51. Malignant Melanoma of Uvea

1. Ciliary Body and Choroid

2. Iris

52. Retinoblastoma
53. Carcinoma of the Lacrimal Gland
54. Sarcoma of the Orbit
55. Ocular Adnexal Lymphoma
56. Lymphoid Neoplasms
1. Hodgkin and Non-Hodgkin Lymphoma

2. Primary Cutaneous Lymphomas

Staging Parameter: Peripheral blood involvement, as collected in CS SSF 1

historical changes